Neoadjuvant Nivolumab Plus Lirilumab For Muscle-Invasive Bladder Cancer

Neoadjuvant Nivolumab Plus Lirilumab for Muscle-Invasive Bladder Cancer

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with m...

Neoadjuvant Chemotherapy Plus Nivolumab and BMS-986205 for Muscle Invasive Bladder Cancer

PrE0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with MIBC

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

Bladder cancer: unmet need for novel therapies

Next Steps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Targeted Oncology

Neoadjuvant Immune Checkpoint Inhibition for Muscle Invasive Bladder Cancer

Grand Rounds in Urology

Immunotherapy for Muscle Invasive Bladder Cancer

Grand Rounds in Urology

Neoadjuvant and Adjuvant Therapy in Muscle-Invasive Bladder Cancer

Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer

Grand Rounds in Urology

Neoadjuvant sacituzumab govitecan for muscle-invasive bladder cancer

Predictive Biomarkers of Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer | Oncotarget

Phase-2 trial of gemcitabine, cisplatin + nivolumab with selective bladder sparing in MIBC patients

European Association of Urology

BLASST-1: nivolumab + gemcitabine-cisplatin before radical cystectomy in muscle-invasive BC

Introduction: Neoadjuvant Chemotherapy in Bladder Cancer

BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant treatment of muscle...

A bladder-sparing approach for muscle-invasive bladder cancer

Concurrent Chemo-Radiation in Muscle Invasive Bladder Cancer

OncBrothers: Practice-Changing Cancer Discussions

Adjuvant Nivolumab After Chemo-Radiation for Localized Muscle-Invasive Bladder Cancer